Schwab Charles CORP Form 4 insider transactions

Jonathan S. Beatty, MD, Head of Advisor Services at Charles Schwab Corp., was granted 24,509 nonqualified stock options with an exercise price of $95.49.

The Charles Schwab Corporation's CFO, Michael D. Verdeschi, was granted 62,134 nonqualified stock options under the company's 2022 Stock Incentive Plan.

Paul V. Woolway, MD, Chief Banking Officer at Charles Schwab, reported multiple stock transactions including vesting of restricted stock units, option exercises, and sales under a pre-arranged trading plan.

Jonathan M. Craig, MD and Head of Investor Services at Charles Schwab, acquired common stock and stock options through performance-based vesting and a a new grant.

Charles Schwab's Chief Risk Officer, Nigel J. Murtagh, reported the vesting of restricted stock units, related tax-driven share disposals, and a new stock option grant.

Dennis Howard, Schwab's MD, Chief Tech, OPS & Data Officer, reported the vesting of performance-based restricted stock units and the grant of new stock options.

Charles R. Schwab, Co-Chairman of The Charles Schwab Corporation, reported the acquisition of common stock through PBRSU vesting and a new stock option grant.

Charles Schwab Co-Chairman Walter W. Bettinger received a significant equity grant from vested performance-based restricted stock units and nonqualified stock options, while also selling shares for tax obligations.

Schwab's President & CEO, Richard A. Wurster, reported the vesting of performance-based restricted stock units and the grant of new stock options, alongside shares withheld for tax obligations.

Charles Schwab's General Counsel, Peter J. Morgan III, reported the vesting of performance-based restricted stock units and the grant of new stock options.

A Charles Schwab executive sold 2,030 shares of common stock for approximately $193,453 under a pre-arranged 10b5-1 trading plan.

A director of Charles Schwab Corporation sold over 10,000 shares of common stock at a weighted average price of $96.5682 per share under a pre-arranged trading plan.

A Charles Schwab executive exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged trading plan.

Charles R. Schwab, Co-Chairman of The Charles Schwab Corporation, reported sales of company common stock totaling 158,613 shares in pre-planned transactions.

Charles Schwab Co-Chairman Walter W. Bettinger exercised stock options and subsequently sold an equal number of shares on February 6, 2026, under a Rule 10b5-1 plan.

Christopher V. Dodds, a Director at The Charles Schwab Corporation, exercised stock options and subsequently sold a portion of his common stock holdings.

Charles R. Schwab, Co-Chairman of The Charles Schwab Corporation, executed pre-planned sales of company common stock totaling over $17 million.

Walter W. Bettinger, II, Co-Chairman of Charles Schwab, exercised stock options and subsequently sold an equivalent number of shares from his family trust.

Peter J. Morgan III, General Counsel at Charles Schwab, reported a future transaction involving the exercise of stock options and the subsequent sale of the acquired common stock.

Charles R. Schwab, Co-Chairman of The Charles Schwab Corporation, reported the sale of 145,650 shares of common stock for approximately $15 million on January 29, 2026, executed under a Rule 10b5-1 plan.

Charles R. Schwab, Co-Chairman of The Charles Schwab Corporation, reported exercising stock options and selling over 200,000 shares of company stock in pre-planned transactions.

A director at The Charles Schwab Corporation sold over 42,000 shares of common stock for approximately $4.5 million through a pre-arranged trading plan.

Jonathan S. Beatty, MD, Head of Advisor Services at Charles Schwab, exercised stock options and subsequently sold shares under a pre-arranged trading plan.

The Charles Schwab Corporation director Marianne Brown received 394 restricted stock units as part of her deferred compensation plan.

Frank C. Herringer, a director at The Charles Schwab Corporation, acquired 431 restricted stock units as part of his director compensation plan.

Charles Schwab Director Stephen A. Ellis acquired 357 Restricted Stock Units as part of his deferred compensation plan, bringing his total beneficial ownership to 12,417.76 RSUs.

Charles A. Ruffel, a Director at The Charles Schwab Corporation, received 1,317 nonqualified stock options with an exercise price of $101.57 as part of his director compensation.

Jonathan S. Beatty, MD and Head of Advisor Services at The Charles Schwab Corporation, exercised stock options and sold common stock on December 23, 2025, under a Rule 10b5-1 plan.

Stephen A. Ellis, a director at The Charles Schwab Corporation, exercised stock options and contributed the acquired shares to a revocable trust.

Charles A. Ruffel, a director at The Charles Schwab Corporation, reported the gift of 8,372 shares of common stock.